ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results

ADC Therapeutics (NYSE:ADCT) announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.28, Zacks reports. The firm had revenue of $23.06 million for the quarter, compared to analyst estimates of $22.29 million.

Here are the key takeaways from ADC Therapeutics’ conference call:

• The company has refocused on ZYNLONTA lifecycle management, cut operating costs by ~50%, upgraded leadership, and strengthened the balance sheet (cash $261M) with a stated runway into 2028.
• Key clinical catalysts ahead — management expects LOTIS-5 top-line PFS data in Q2 2026, and LOTIS-7 showed a 90% ORR and 78% CR in 49 evaluable patients with enrollment expanded to ~100.
• Commercially, 2025 net product revenues were $73.6M (Q4 $22.3M) with volumes broadly flat and an estimated ~10% share in third-line DLBCL; management expects stability until label expansion.
• Despite reduced expenses and a narrower GAAP loss, the company reported a full-year net loss of $142.6M and future upside depends on regulatory approvals, compendia inclusion and competition from bispecifics, posing execution risk.

ADC Therapeutics Stock Performance

Shares of ADCT traded down $0.01 during mid-day trading on Thursday, reaching $3.96. 174,763 shares of the company were exchanged, compared to its average volume of 807,440. The business has a 50 day simple moving average of $4.01 and a two-hundred day simple moving average of $3.94. The stock has a market capitalization of $503.71 million, a PE ratio of -3.30 and a beta of 1.92. ADC Therapeutics has a 52 week low of $1.05 and a 52 week high of $4.98.

Institutional Trading of ADC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its holdings in ADC Therapeutics by 141.6% during the 4th quarter. Nantahala Capital Management LLC now owns 5,475,433 shares of the company’s stock worth $19,328,000 after purchasing an additional 3,209,144 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of ADC Therapeutics during the third quarter worth $5,561,000. Lynx1 Capital Management LP acquired a new stake in shares of ADC Therapeutics during the third quarter worth $5,303,000. Prosight Management LP raised its stake in ADC Therapeutics by 13.5% during the fourth quarter. Prosight Management LP now owns 8,477,338 shares of the company’s stock worth $29,925,000 after buying an additional 1,005,035 shares during the last quarter. Finally, Schroder Investment Management Group acquired a new position in ADC Therapeutics in the fourth quarter valued at $1,466,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. HC Wainwright boosted their target price on shares of ADC Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $5.00 price target on shares of ADC Therapeutics in a research report on Wednesday, December 3rd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.